An observational study in Neuroblastoma, sponsored by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 469 studies in Neuroblastoma with a site in United States — 54 open to participants now, 103 under way, 4 of them phase 3. Neuroblastoma · United States.
Among the 469 studies in Neuroblastoma with a site in United States, this one is the 35th largest by enrollment of the 48 observational ones that give a count, is one of 10 that started in 2026, is one of 48 observational ones, and was the 468th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →54 of the 469 studies in Neuroblastoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 1–30
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 1–39
Giselle Sholler · Sites in United States
Ages 1–30
Robbie Majzner · Sites in United States
Ages 9 mo–30 yrs
Baylor College of Medicine · Sites in United States
Ages 1–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
469 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 222 · Phase 2 178 · Phase 3 26 · Phase 4 1
First in 1987; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 123 across 84 observational studies indexed under Neuroblastoma.
Median enrollment 31 across the 379 interventional studies, 202 across the 48 observational. Of the 331 that completed or were terminated, 109 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 469 have an industry lead sponsor. The 10 most frequent:
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) has 3 studies filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
31 of the studies in Neuroblastoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02307630Memorial Sloan Kettering Cancer CenterPET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT04211675Nationwide Children's HospitalNK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | 2026-12 |
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT02298348New Approaches to Neuroblastoma Therapy ConsortiumSorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 469 studies in Neuroblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective image revaluation study designed to assess the performance of 18F-mFBG PET imaging in detecting the presence of neuroblastoma. Eligible participants will have undergone 18F-mFBG PET imaging in a research trial or locally-authorized clinical use and have: a) an established diagnosis of active neuroblastoma; or b) an established diagnosis of neuroblastoma in remission; or c) no history or current evidence of neuroblastoma based on signs, symptoms, imaging findings, and laboratory results.
This is a study involving blinded interpretation of existing 18F-mFBG PET images. No subjects will be administered 18F-mFBG. Previously collected 18F-mFBG PET studies will be evaluated by 5 independent radiologists and/or nuclear medicine physicians. They will have access to limited clinical information on the reason subject was undergoing evaluations at the time of 18F-mFBG imaging but be blinded to all other subject information. Blinded readers will record the findings on 18F-mFBG scans judged consistent with presence of neuroblastoma and the disease status (+ or -) of the subjects.
Subject-level performance of 18F-mFBG PET will be assessed on the basis of positive and negative percent agreement with presence of at least 1 lesion identified by a blinded reader confirmed as neuroblastoma on clinical standard-of-care imaging and histopathology evaluations. Region/organ system level diagnostic performance will be assessed on the basis of positive and negative percent agreement between the blinded 18F-mFBG scan interpretations and disease status in the corresponding region on clinical standard-of-care imaging and histopathology evaluations. Both assessments will utilize the clinical information gathered as part of the trials or locally-authorized clinical use in which the 18F-mFBG scans were acquired and relevant clinical follow-up available at the imaging sites.
The planned population will consist of subjects with previously established presence or absence of active neuroblastoma. Individuals enrolled as healthy controls in 18F-mFBG trials may be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease status (+ or - for neuroblastoma) as of the date of 18F-mFBG imaging was established based on data collected as part of the previous clinical trial or locally-authorized clinical use or during subsequent clinical follow-up.
Exclusion Criteria:
- 1. There is insufficient correlative imaging and clinical follow-up data to establish subject disease status as of the date of 18F-mFBG imaging.
2. 18F-mFBG imaging from the previous trial was judged incomplete or uninterpretable.
Subjects previously administered 18F-mFBG with: a) a current diagnosis of neuroblastoma; b) a diagnosis of neuroblastoma in remission; or c) no history or current evidence of neuroblastoma.
Drug: 18F-MFBG
Quantity of 18F-mFBG administered to each subject was determined based on the protocol specifications of the original trial at each participating site. No 18F-mFBG will be administered in this study.
Determine Sensitivity, Specificity, Positive and Negative Predictive Percent Agreement (PPA/NPA) of 18F-mFBG
The primary objective of this study is to demonstrate that 18F-mFBG PET scintigraphy (PET/CT or PET/MR) is sensitive and specific (in terms of positive and negative percent agreement (PPA and NPA) on a subject-level in confirming or excluding the presence of neuroblastoma.
Time frame: Blinded Reader review over 2-3 weeks.
PPA/NPA on a region/organ system level
To demonstrate that 18F-mFBG PET scintigraphy (PET/CT or PET/MR) is sensitive and specific (in terms of positive and negative percent agreement (PPA and NPA)) on a region/organ system level in confirming or excluding the presence of neuroblastoma.
Time frame: Blinded reader evaluation over 2-3 weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2026 to primary completion in Jul 2026, 1 month.
Of 34 observational studies under Neuroblastoma, half reached primary completion within 213 months of starting (the median), counting those still running; a quarter within 74 and three quarters within 304. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)